141 related articles for article (PubMed ID: 38010402)
21. Metastatic Risk Stratification of 2526 Medullary Thyroid Carcinoma Patients: A Study Based on Surveillance, Epidemiology, and End Results Database.
Le MK; Kawai M; Odate T; Vuong HG; Oishi N; Kondo T
Endocr Pathol; 2022 Sep; 33(3):348-358. PubMed ID: 35852678
[TBL] [Abstract][Full Text] [Related]
22. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
[TBL] [Abstract][Full Text] [Related]
23. Necrosis is an independent predictor of disease-free and overall survival in pancreatic well-differentiated neuroendocrine tumours (NETs): a proposal to include it in grading systems.
Fuchs TL; Chou A; Ahadi M; Sheen A; Sioson L; Mittal A; Samra J; Gill AJ
Pathology; 2022 Dec; 54(7):855-862. PubMed ID: 35934531
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center.
Raue F; Bruckner T; Frank-Raue K
J Clin Endocrinol Metab; 2019 Oct; 104(10):4264-4272. PubMed ID: 31145454
[TBL] [Abstract][Full Text] [Related]
25. A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio.
Xu P; Wu D; Liu X
Endocrine; 2023 Jul; 81(1):107-115. PubMed ID: 36823341
[TBL] [Abstract][Full Text] [Related]
26. High Ratio of Early Postoperative Calcitonin to Preoperative Calcitonin Could be a Novel Indicator of Poor Prognosis in Patients with Biochemical Incomplete Responses in Sporadic Medullary Thyroid Cancer.
Chen L; Sun W; Qian K; Guo K; Sun T; Wu YI; Wang Z
Endocr Pract; 2020 Jul; 26(7):738-747. PubMed ID: 33471642
[TBL] [Abstract][Full Text] [Related]
27. Ki67 proliferation index in medullary thyroid carcinoma: a comparative study of multiple counting methods and validation of image analysis and deep learning platforms.
Nadeem S; Hanna MG; Viswanathan K; Marino J; Ahadi M; Alzumaili B; Bani MA; Chiarucci F; Chou A; De Leo A; Fuchs TL; Lubin DJ; Luxford C; Magliocca K; Martinez G; Shi Q; Sidhu S; Al Ghuzlan A; Gill AJ; Tallini G; Ghossein R; Xu B
Histopathology; 2023 Dec; 83(6):981-988. PubMed ID: 37706239
[TBL] [Abstract][Full Text] [Related]
28. Distant metastasis in medullary thyroid carcinoma: Clinical outcomes and implications of T stage.
Shao Y; Li G; Wei T; Gong R; Li Z; Zhu J; Lei J
Clin Endocrinol (Oxf); 2022 Nov; 97(5):676-684. PubMed ID: 35261045
[TBL] [Abstract][Full Text] [Related]
29. Papillary and Medullary Thyroid Carcinomas Presenting as Collision Tumors: A Case Series of 21 Cases at a Tertiary Care Cancer Center.
Thomas A; Mittal N; Rane SU; Bal M; Patil A; Ankathi SK; Vaish R
Head Neck Pathol; 2021 Dec; 15(4):1137-1146. PubMed ID: 33840044
[TBL] [Abstract][Full Text] [Related]
30. Surgical management of medullary thyroid carcinoma.
Konstantinidis A; Stang M; Roman SA; Sosa JA
Updates Surg; 2017 Jun; 69(2):151-160. PubMed ID: 28409442
[TBL] [Abstract][Full Text] [Related]
31. Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single-Institution Study in Japan.
Ito Y; Miyauchi A; Kihara M; Higashiiyama T; Fukushima M; Miya A
World J Surg; 2018 Dec; 42(12):3954-3966. PubMed ID: 30051240
[TBL] [Abstract][Full Text] [Related]
32. Risk and survival of patients with medullary thyroid cancer: National perspective.
Al-Qurayshi Z; Khadra H; Chang K; Pagedar N; Randolph GW; Kandil E
Oral Oncol; 2018 Aug; 83():59-63. PubMed ID: 30098780
[TBL] [Abstract][Full Text] [Related]
33. Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.
Kuo EJ; Sho S; Li N; Zanocco KA; Yeh MW; Livhits MJ
JAMA Surg; 2018 Jan; 153(1):52-59. PubMed ID: 28973144
[TBL] [Abstract][Full Text] [Related]
34. Incidental T1 stage medullary thyroid carcinoma: The effect of tumour diameter on prognosis and therapeutic implications.
Gui Z; Wang Z; Xiang J; Sun W; He L; Dong W; Huang J; Zhang D; Lv C; Zhang T; Shao L; Zhang P; Zhang H
Clin Endocrinol (Oxf); 2022 Sep; 97(3):355-362. PubMed ID: 35192214
[TBL] [Abstract][Full Text] [Related]
35. Clinical, pathologic, and immunohistochemical prognostic factors in dogs with thyroid carcinoma.
Campos M; Ducatelle R; Rutteman G; Kooistra HS; Duchateau L; de Rooster H; Peremans K; Daminet S
J Vet Intern Med; 2014; 28(6):1805-13. PubMed ID: 25252127
[TBL] [Abstract][Full Text] [Related]
36. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
37. Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study.
Twito O; Grozinsky-Glasberg S; Levy S; Bachar G; Gross DJ; Benbassat C; Rozental A; Hirsch D
Eur J Endocrinol; 2019 Jul; 181(1):13-21. PubMed ID: 31048559
[TBL] [Abstract][Full Text] [Related]
38. Medullary thyroid cancer: epidemiological pattern and factors contributing to recurrence and metastasis.
Hamdy O; Awny S; Metwally IH
Ann R Coll Surg Engl; 2020 Sep; 102(7):499-503. PubMed ID: 32233867
[TBL] [Abstract][Full Text] [Related]
39. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
40. Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease.
Jayakody S; Reagh J; Bullock M; Aniss A; Clifton-Bligh R; Learoyd D; Robinson B; Delbridge L; Sidhu S; Gill AJ; Sywak M
World J Surg; 2018 May; 42(5):1432-1439. PubMed ID: 29484475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
